Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: a qualitative interview study.

Hepgul N, Kodate N, Anderson JE, Henderson M, Ranjith G, Hotopf M, Pariante CM.

Int J Nurs Stud. 2012 Dec;49(12):1480-8. doi: 10.1016/j.ijnurstu.2012.07.016. Epub 2012 Aug 11.

PMID:
22889554
2.

Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C.

Galvão-de Almeida A, Quarantini LC, Sampaio AS, Lyra AC, Parise CL, Paraná R, de Oliveira IR, Koenen KC, Miranda-Scippa A, Guindalini C.

Brain Behav Immun. 2011 Oct;25(7):1491-7. doi: 10.1016/j.bbi.2011.06.001. Epub 2011 Jun 15.

3.
4.

Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.

Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D, Shippam A.

Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250. Review.

5.

L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.

Neri S, Pistone G, Saraceno B, Pennisi G, Luca S, Malaguarnera M.

Neuropsychobiology. 2003;47(2):94-7.

PMID:
12707492
6.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
7.

Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression.

Hauser P.

Gastroenterol Clin North Am. 2004 Mar;33(1 Suppl):S35-50.

PMID:
15081102
8.

A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C.

Loftis JM, Wall JM, Linardatos E, Benvenga S, Hauser P.

J Endocrinol Invest. 2004 Jul-Aug;27(7):RC16-20.

PMID:
15505982
9.

Monitoring depression in patients undergoing alpha-interferon and ribavirin therapy for hepatitis C.

Wright IA.

Gastroenterol Nurs. 2000 Nov-Dec;23(6):275-80. Review.

PMID:
11854972
10.

Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.

Maddock C, Baita A, Orrù MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM.

J Psychopharmacol. 2004 Mar;18(1):41-6.

PMID:
15107183
11.

Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study.

Hopwood M.

Psychol Health Med. 2013;18(6):742-50. doi: 10.1080/13548506.2013.774429. Epub 2013 Mar 5.

PMID:
23458315
12.

Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser.

Kalyoncu OA, Tan D, Mirsal H, Pektas O, Beyazyurek M.

J Psychopharmacol. 2005 Jan;19(1):102-5.

PMID:
15671136
13.

Can antidepressants prevent interferon-alpha-induced depression? A review of the literature.

Galvão-de Almeida A, Guindalini C, Batista-Neves S, de Oliveira IR, Miranda-Scippa A, Quarantini LC.

Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):401-5. doi: 10.1016/j.genhosppsych.2010.03.001. Epub 2010 Apr 2. Review.

PMID:
20633744
14.

Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.

Czerwionka-Szaflarska M, Chrobot A, Szaflarska-Szczepanik A.

Med Sci Monit. 2000 Sep-Oct;6(5):964-70.

PMID:
11208439
15.

Clinical decision-making of rural novice nurses.

Seright TJ.

Rural Remote Health. 2011;11(3):1726. Epub 2011 Jul 21.

16.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
17.

Frequency of depression and somatic symptoms in patients on interferon alpha/ribavirin for chronic hepatitis C.

Shakoor A, Shafqat F, Mehmud Te, Akram M, Riaz S, Iqbal Z, Khan AA.

J Ayub Med Coll Abbottabad. 2010 Oct-Dec;22(4):6-9.

PMID:
22455250
18.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
19.

Views of hepatitis C virus patients delayed from treatment for psychiatric reasons.

Rowan PJ, Dunn NJ, El-Serag HB, Kunik ME.

J Viral Hepat. 2007 Dec;14(12):883-9.

PMID:
18070292
20.

[Neuro-immune interactions in psychopathology with the example of interferon-alpha-induced depression].

Capuron L, Dantzer R, Miller AH.

J Soc Biol. 2003;197(2):151-6. Review. French.

PMID:
12910630

Supplemental Content

Support Center